Successful use of vincristine in the management of Kasabach-Merritt Phenomenon

Year 2012, Volume: 19 Issue: 2, 55 - 58, 30.06.2012

M Asim Aydın Ayca Kuybulu Aslihan Boyacı Tugba Koca

Abstract

A 2-month old boy with Kaposiform Hemangioendothelioma of the lumbosacral region invading the retroperitoneum was admitted with Kasabach-Merritt Phenomenon. After corticosteroid and interferon treatments failed with progression of the disease to a life threatening condition, vincristine monotreatment granted a rapid rise in platelet counts, fibrinogen levels and a resolution in the enlargement of the lesion. The remission was maintained and no adverse effects were observed during the treatment. Vincristin therapy may be suggested instead of multidrugs as first line therapy in patients with KMP.

Keywords

Kasabach Merrit Fenomeni, Vincristin

References

• Hall GW: Kasabach-Merritt syndrome: pathogenesis and management. Br J Haematol 2001;112(4):851- 862.
• Kwok-Williams M, Perez Z, Squire R, Glaser A, Bew S, Taylor R. Radiotherapy for life-threatening mediastinal hemangioma with Kasabach-Merritt syndrome. 2007;49(5):739-44.
• Chung T, Hoffer FA, Burrows PE, et al. MR imaging of hepatic hemangiomas of infancy and changes seen with interferon alpha-2a treatment. Pediatr Radiol 1996;26(5):341-348.
• Akyuz C, Yaris N, Kutluk MT, et al. Management of cutaneous hemangiomas: a retrospective analysis of 1109 cases and comparison of conventional dose prednisolone with high-dose methylprednisolone therapy. Pediatr Hematol Oncol 2001;18(1): 47-55.
• Koerper MA, Addiego JE Jr, deLorimier AA, et al. Use of aspirin and dipyridamole in children with platelet trapping syndromes. J Pediatr 1983;102(2):311-314.
• Prost Y, Teillac D, Bodemer C, et al. Successful treatment of Kasabach -Merritt syndrome with pentoxifylline. J Am Acad Dermatol 1991;25(5 Pt 1):854-855.
• Dresse MF, David M, Hume H, et al. Successful treatment of Kasabach -Merritt syndrome with prednisone and epsilon-aminocaproic acid. Pediatr Hematol Oncol 1991;8(4):329-334.
• Ezekowitz A, Mulliken J, Folkman J. Interferon alpha therapy of haemangiomas in newborns and infants. Br J Haematol 1991;79(Suppl 1):67-68.
• Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992;326(22):1456-1463.
• Harper L, Michel JL, Enjolras O, Raynaud-Mounet N, Rivière JP, Heigele T, De Napoli-Cocci S. Successful management of a retroperitoneal kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon using alpha-interferon. Eur J Pediatr Surg. 2006;16(5):369-72.
• Haisley-Royster C, Enjolras O, Frieden IJ, Garzon M, Lee M, Oranje A, de Laat PC, Madern GC, Gonzalez F, Frangoul H, Le Moine P, Prose NS, Adams DM. Kasabach-Merritt phenomenon: a retrospective study of treatment with vincristine. J Pediatr Hematol Oncol 2002;24(6):459-462.
• Abass K, Saad H, Kherala M, Abd-Elsayed AA. Successful treatment of kasabach-merritt syndrome with vincristine and surgery: a case report and review of literature. Cases J 2008;1(1):9.
• Yesudian PD, Parslew R, Klafowski J, Gould D, Pizer B. Tufted angioma-associated Kasabach-Merritt syndrome treated with embolization and vincristine. P l a s t R e c o n s t r S u rg . 2 0 0 8 ; 1 2 1 ( 2 ) : 6 9 2 - 3 .
• Thomson K, Pinnock R, Teague L, Johnson R, Manikkam N, Drake R. Vincristine for the treatment of Kasabach-Merritt syndrome: recent New Zealand case experience. N Z Med J. 2007;120(1249):U2418.
• Taki M, Ohi C, Yamashita A, Kobayashi M, Kobayashi N, Yoda T, Horiuchi T, Aikyou M, Horikoshi Y, Mimaya J. Successful treatment with vincristine of an infant with intractable Kasabach-Merritt syndrome. Pediatr Int. 2006;48(1):82-4.
• Hoyoux C: Vincristine treatment for management of alarming hemangiomas in infancy. Rev Med Liege.2008;63(1):14-7.